VCANBIO CELL & GENE ENGINEERING CORP., LTD

Vcanbio Cell & Gene Engineering Corp., Ltd

Equities

600645

CNE000000545

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
17.43 ^CNY	-0.11%		-1.80%	-14.01%

04-25	Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04-25	Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Zhongyuan Union Cell & Gene Engineering Corp., Ltd Provides Earnings Guidance for Year 2016

January 15, 2017

Zhongyuan Union Cell & Gene Engineering Corp. Ltd. provided earnings guidance for year 2016. The company predicts that the net profit owned by shareholders of the company in 2016 will be about RMB 45.36 million and earnings per share will be about RMB 0.12, with a decrease of 78.23% compared with that of 2015.

Latest news about Vcanbio Cell & Gene Engineering Corp., Ltd

Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	04-19	CI
Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback announced on February 19, 2024, has closed with 6,181,212 shares, representing 1.32% for CLP 100 million.	04-17	CI
Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.	04-01	CI
Vcanbio Cell & Gene Engineering Corp., Ltd announces an Equity Buyback for CLP 200 million worth of its shares.	02-19	CI
Vcanbio Cell & Gene Engineering Corp., Ltd authorizes a Buyback Plan	02-16	CI
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it has received CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd	12-25	CI
Shanghai Vcanbio Jisheng Cell Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Vcanbio Cell & Gene Engineering Corp., Ltd	11-07	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
Vcanbio Cell & Gene Gets Greenlight to Trial COVID-19 Drug	16/10/23	MT
Vcanbio Cell & Gene Engineering Corp., Ltd agreed to acquire additional 3% stake in Heyuan Biological Technology Co., Ltd. from Beijing Fuyuan Zhiyuan Biotechnology Partnership (Limited Partnership).	28/09/23	CI
Vcanbio Cell & Gene Engineering Corp., Ltd(XSSC:600645) added to S&P Global BMI Index	18/09/23	CI
MET Group signs energy supply deal with Commonwealth LNG	04/09/23	RE
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23	CI
Vcanbio Cell & Gene’s Pulmonary Fibrosis Treatment Wins Orphan Drug Designation in US	14/08/23	MT
Vcanbio Cell & Gene Unit Gets Nod to Begin Clinical Trial of Respiratory Distress Medication	08/06/23	MT
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25/04/23	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	25/04/23	CI
Vcanbio Cell & Gene Engineering Wins Nod to Trial Stem Cell Therapy For Liver Cirrhosis	13/02/23	MT
C-Mer Eye Care Raises HK$116.1 Million in Share Subscription Deal	09/12/22	MT
C-Mer Eye Care To Issue More Than 30 Million New Shares to Vcanbio Cell Chairman	05/12/22	MT
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22	CI
Vcanbio Cell & Gene Engineering Corp., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI
Energy firms MET and HH2E to invest in Baltic electrolysis plant	15/06/22	RE

Chart Vcanbio Cell & Gene Engineering Corp., Ltd

Duration

Period

Chart Vcanbio Cell & Gene Engineering Corp., Ltd

More charts

Company Profile

VCANBIO CELL & GENE ENGINEERING CORP., LTD is a China-based company, principally engaged in the preparation, detection and storage of cells. The Company is also engaged in cell culture and gene detection and storage, as well as the production and sale of cytokines culture solutions, cosmetics and detection reagents. The Company conducts its businesses mainly within domestic markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
VCANBIO CELL & GENE ENGINEERING CORP., LTD	-14.01%	1.11B
BIOMÉRIEUX	-3.43%	12.1B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.17%	8.24B
LANTHEUS HOLDINGS, INC.	+31.98%	5.58B
AUTOBIO DIAGNOSTICS CO., LTD.	-10.03%	4.15B
10X GENOMICS, INC.	-59.94%	2.68B
ANDON HEALTH CO., LTD.	+11.23%	2.63B
VITROLIFE AB	-5.14%	2.24B
MYRIAD GENETICS, INC.	+18.91%	2.03B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-7.56%	1.79B

Diagnostic & Testing Substances